Literature DB >> 7595214

Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.

B Wizel1, R A Houghten, K C Parker, J E Coligan, P Church, D M Gordon, W R Ballou, S L Hoffman.   

Abstract

Vaccines designed to protect against malaria by inducing CD8+ cytotoxic T lymphocytes (CTL) in individuals of diverse HLA backgrounds must contain multiple conserved epitopes from various preerythrocytic-stage antigens. Plasmodium falciparum sporozoite surface protein 2 (PfSSP2) is considered an important antigen for inclusion in such vaccines, because CD8+ CTL against the P. yoelii SSP2 protect mice against malaria by eliminating infected hepatocytes. To develop PfSSP2 as a component of malaria vaccines, we investigated the presence of anti-PfSSP2 CTL in two HLA-B8+ volunteers immunized with irradiated P. falciparum sporozoites and characterized their CTL responses using PfSSP2-derived 15-amino acid peptides bearing the HLA-B8-binding motif. Peripheral blood mononuclear cells from both volunteers stimulated with recombinant vaccinia expressing PfSSP2 displayed antigen-specific, genetically restricted, CD8+ T cell-dependent CTL activity against autologous target cells expressing PfSSP2. Of the five HLA-B8 motif-bearing 15-mers identified in the PfSSP2 sequence, two peptides sharing a 10-amino acid overlap sensitized HLA-B8-matched target cells from both volunteers for lysis by peptide-stimulated effectors. The CTL activity was HLA-B8 restricted and dependent on CD8+ T cells. Analysis of the three shorter peptides representing HLA-B8 motif-bearing sequences within the two positive peptides for their ability to bind to HLA-B8 in vitro, and to sensitize target cells for lysis by effectors stimulated with the 15-mers, identified two overlapping HLA-B8-restricted CTL epitopes. Available data indicate that the sequence of one CTL epitope is conserved and the other is variant among P. falciparum isolates. Circulating activated CTL against the conserved epitope could be directly identified in one of the two volunteers. The identification of two HLA-B8-restricted CTL epitopes on PfSSP2 provides data critical to developing an epitope-based anti-liver stage malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595214      PMCID: PMC2192212          DOI: 10.1084/jem.182.5.1435

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  62 in total

1.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

2.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.

Authors:  A Bertoletti; C Ferrari; F Fiaccadori; A Penna; R Margolskee; H J Schlicht; P Fowler; S Guilhot; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Location of human cytotoxic T cell epitopes within a polymorphic domain of the Plasmodium falciparum circumsporozoite protein.

Authors:  D L Doolan; R A Houghten; M F Good
Journal:  Int Immunol       Date:  1991-06       Impact factor: 4.823

4.  CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria.

Authors:  M M Rodrigues; A S Cordey; G Arreaza; G Corradin; P Romero; J L Maryanski; R S Nussenzweig; F Zavala
Journal:  Int Immunol       Date:  1991-06       Impact factor: 4.823

5.  Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein.

Authors:  A Malik; J E Egan; R A Houghten; J C Sadoff; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  Polymorphism of the TRAP gene of Plasmodium falciparum.

Authors:  K J Robson; J R Hall; L C Davies; A Crisanti; A V Hill; T E Wellems
Journal:  Proc Biol Sci       Date:  1990-12-22       Impact factor: 5.349

7.  Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein.

Authors:  S Khusmith; Y Charoenvit; S Kumar; M Sedegah; R L Beaudoin; S L Hoffman
Journal:  Science       Date:  1991-05-03       Impact factor: 47.728

8.  Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes.

Authors:  S L Hoffman; D Isenbarger; G W Long; M Sedegah; A Szarfman; L Waters; M R Hollingdale; P H van der Meide; D S Finbloom; W R Ballou
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

9.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

Authors:  B D Walker; C Flexner; K Birch-Limberger; L Fisher; T J Paradis; A Aldovini; R Young; B Moss; R T Schooley
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes.

Authors:  E G Pamer; J T Harty; M J Bevan
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

View more
  25 in total

1.  HLA-A*01-restricted cytotoxic T-lymphocyte epitope from the Plasmodium falciparum circumsporozoite protein.

Authors:  A Kumar; S Kumar; T P Le; S Southwood; J Sidney; J Cohen; A Sette; S L Hoffman
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids.

Authors:  R Wang; D L Doolan; Y Charoenvit; R C Hedstrom; M J Gardner; P Hobart; J Tine; M Sedegah; V Fallarme; J B Sacci; M Kaur; D M Klinman; S L Hoffman; W R Weiss
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 3.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

4.  Lewis X oligosaccharides targeting to DC-SIGN enhanced antigen-specific immune response.

Authors:  Jingxue Wang; Yongmin Zhang; Jing Wei; Xiaoping Zhang; Bei Zhang; Zhenyuan Zhu; Wei Zou; Yiqin Wang; Zhirong Mou; Bin Ni; Yuzhang Wu
Journal:  Immunology       Date:  2007-03-20       Impact factor: 7.397

5.  Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes.

Authors:  Y Charoenvit; V Fallarme; W O Rogers; J B Sacci; M Kaur; J C Aguiar; L F Yuan; G Corradin; E Andersen; B Wizel; R A Houghten; A Oloo; P De la Vega; S L Hoffman
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis.

Authors:  A Lalvani; R Brookes; R J Wilkinson; A S Malin; A A Pathan; P Andersen; H Dockrell; G Pasvol; A V Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

7.  Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses.

Authors:  B Wizel; M Palmieri; C Mendoza; B Arana; J Sidney; A Sette; R Tarleton
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

8.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

Review 9.  Genetically engineered, attenuated whole-cell vaccine approaches for malaria.

Authors:  Ashley M Vaughan; Ruobing Wang; Stefan H I Kappe
Journal:  Hum Vaccin       Date:  2010-01-29

10.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.